THERAFLEX UV-Platelets: A breakthrough in blood transfusion safety and efficiency

THERAFLEX UV-Platelets: A breakthrough in blood transfusion safety and efficiency

Yvan Malepart, President and CEO Macopharma

Watch the video

Yvan Malépart, Chief Executive Officer of Macopharma, explains the strategy behind the development of THERAFLEX UV-Platelets.

What are Macopharma’s main objectives for THERAFLEX UV-Platelets?

YM: “Patients have been at the heart of our activities, ever since the company was founded in 1977. Over the years, we have used our expertise to bring new solutions to patients – and we are following in those footsteps. THERAFLEX UV-Platelets gives us the possibility to reinforce our position as a leader in blood transfusion products and services – and to provide a unique solution to patients.”

What contribution can THERAFLEX UV-Platelets make to public health?

YM: “Blood transfusion is a critical building block of healthcare, so THERAFLEX UV-Platelets will make a significant contribution to public health and will give patients peace of mind by making safe, high-quality blood products readily available. At the same time, it will offer a very cost-effective solution for healthcare providers.”

THERAFLEX UV-Platelets will make a significant contribution to public health and will give patients peace of mind… At the same time, it will offer a very cost-effective solution for healthcare providers.”

Where does it fit in the Macopharma portfolio, and the blood transfusion sector in general?

YM: “THERAFLEX UV-Platelets will be an important part of our future and will complement our existing range of blood processing, biotherapy and hospital products in a very impactful way. In the world of blood transfusion, it is a revolution in the production of platelet concentrates. As the only technology to provide inactivation without the use of a reagent, it is a game-changer.”

What are the prospects for THERAFLEX UV-Platelets?

YM: “We expect it to have a major impact in multiple regions around the world. Given the increasing number of emerging pathogens, we expect health authorities to move to pathogen inactivation – rather than testing or screening – for their blood products.

In Europe, we expect to see an early uptake, since the clinical trial and our production facilities are here. However, the efficiency gains from eliminating the reagent, along with the time savings in concentrate preparation, should make North America and the leading Asia economies a positive environment for us. Meanwhile, the broad spectrum of impact of our solution will bring tremendous value to emerging markets. In short, every region will see value in THERAFLEX UV-Platelets.”

Menu